Table 2 Baseline characteristics of patients with or without irAEs in the combination therapy and monotherapy groups
Patients with combination therapy, No. (%) | Patients with monotherapy, No. (%) | |||||
|---|---|---|---|---|---|---|
Patients with irAE (n = 46) | Patients without irAE (n = 28) | P value | Patients with irAE (n = 40) | Patients without irAE (n = 34) | P value | |
Age, median (range), years | 68 (33–80) | 63.5 (40–72) | < 0.01 | 74 (54–88) | 69 (46–85) | 0.01 |
Sex, no. (%) | ||||||
Male | 34 (73.9) | 20 (71.4) | 0.82 | 30 (75.0) | 23 (53.6) | 0.48 |
Female | 12 (26.1) | 8 (28.6) | 10 (25.0) | 11 (32.4) | ||
Smoking status, no. (%) | ||||||
Current or Former | 44 (95.7) | 25 (89.3) | 0.29 | 38 (95.0) | 29 (85.3) | 0.16 |
Never | 2 (4.3) | 3 (10.7) | 2 (5.0) | 5 (14.7) | ||
Performance status, no. (%) | ||||||
0 or 1 | 41 (89.1) | 28 (100) | 0.07 | 35 (87.5) | 23 (67.6) | 0.04 |
≥ 2 | 5 (10.9) | 0 (0) | 5 (12.5) | 11 (32.4) | ||
Histological features, no. (%) | ||||||
Non-squamous cell carcinoma | 35 (76.1) | 23 (82.1) | 0.54 | 29 (72.5) | 24 (70.6) | 0.86 |
Squamous cell carcinoma | 11 (23.9) | 5 (17.9) | 11 (14.9) | 10 (29.4) | ||
Recurrent after surgery, no. (%) | 14 (30.4) | 5 (17.9) | 0.23 | 10 (25.0) | 15 (44.1) | 0.08 |
PD-L1 TPS, no. (%) | ||||||
≥ 50% | 12 (26.1) | 9 (32.1) | 0.58 | 37 (92.5) | 29 (85.3) | 0.32 |
< 50% or unknown | 34 (73.9) | 19 (67.9) | 3 (7.5) | 5 (14.7) | ||